Viral Hepatitis Open Access
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 15, 2003; 9(10): 2216-2220
Published online Oct 15, 2003. doi: 10.3748/wjg.v9.i10.2216
Lethiferous effects of a recombinant vector carrying thymidine kinase suicide gene on 2.2.15 cells via a self-modulating mechanism
Quan-Cheng Kan, Yan-Chang Lei, Lian-Jie Hao, Dong-Liang Yang, Division of Clinical Immunology, Tongji Hospital; Institute of Immunolgy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Zu-Jiang Yu, Department of Infectious Diseases, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: All authors contributed equally to the work.
Supported by the State Key Basic Research Program of China (973 Program, No. 20014CB51008 ) and National Key R & D Program of China for the 10th Five-Year Plan Period (No. 2001BA705B05)
Correspondence to: Dr. Dong-Liang Yang, Division of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Avenue, Wuhan 430030, Hubei Province, China. dlyang@tjh.tjmu.edu.cn
Telephone: +86-27-83662894
Received: July 18, 2003
Revised: July 28, 2003
Accepted: August 7, 2003
Published online: October 15, 2003

Abstract

AIM: To determine the lethiferous effects of a recombinant vector carrying thymidine kinase (TK) suicide gene on 2.2.15 cells and the possible self-modulating mechanism.

METHODS: A self-modulated expressive plasmid pcDNA3-SCITK was constructed by inserting the fragments carrying hepatitis B virus antisense-S (HBV-anti-S) gene, hepatitis C virus core (HCV-C) gene, internal ribosome entry site (IRES) element of HCV and TK gene into the eukaryotic vector pcDNA3, in which the expression of TK suicide gene was controlled by the HBV S gene transcription. 2.2.15 cells that carry the full HBV genome and stably express series of HBV antigen were transfected with pcDNA3-SCITK or vector pcDNA3-SCI which was used as the mock plasmid. The HepG2 cells transfected with pcDNA3-SCITK were functioned as the negative control. All the transfected cells were incubated in DMEM medium supplemented with 10 μg/mL. of ganciclovir (GCV). The HBsAg levels in the supernatant of cell culture were detected by ELISA on the 1st, 3rd and 6th day post-transfection. Meanwhile, the morphology of tranfected cells was recorded by the photograph and the survival cell ratio was assessed by the trypan blue exclusion test on the 6th day post-transfection.

RESULTS: The structural accuracy of pcDNA3-SCITK was confirmed by restriction endonuclease digestion, PCR with specific primers and DNA sequencing. The HBsAg levels in the supernatant of transfected 2.2.15 cell culture were significantly decreased on the 6th day post-transfection as compared with that of the mock control (P < 0.05). The lethiferous effect of pcDNA3-SCITK expression on 2.2.15 cells was initially noted on the 3rd day after transfection and aggravated on the 6th day post transfection, in which the majority of transfected 2.2.15 cells were observed shrunken, round in shape and even dead. With assessment by the trypan blue exclusion test, the survival cell ratio on the 6th day post transfection was 95% in the negative control and only 11% in the experimental group.

CONCLUSION: The results indicate that suicide gene expression of pcDNA3-SCITK can only respond to HBV-S gene transcription, which may be potentially useful in the treatment of HBV infection and its related liver malignancies.




INTRODUCTION

Despite the availability of efficient vaccines, chronic hepatitis B virus (HBV) infection remains a major public health problem worldwide[1-7]. The World Health Organization estimates that there are still 350 million chronic carriers of the virus who are at risk of developing chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[8,9]. This issue is also an important problem in China. The carrier rates of HBsAg are estimated to be as high as more than 10% of Chinese population and a substantial proportion of liver cancer incidence is associated with chronic HBV infection[10-12]. Currently interferon-alpha (IFN-α), an immunomodulator, and two synthetic nucleoside analogues, lamivudine and adefovir dipivoxil, are the only licensed antiviral agents for the treatment of chronic HBV infection. However, this therapeutical modality is still problematic. In addition to the standard treatment endpoints being achievable only in approximately 20%-30% of those treated with either type of agents, interferon usually confers serious side effects, and lamivudine is associated with the occurrence of viral mutations and drug-resistant strains[13-17]. Thus, there is an urgent need for the development of more effective modalities to deal with HBV infection. As yet, several therapeutic protocols with molecular biological techniques have been tried in experimental studies of this disease in the last few years[1,18-25], although significant progress remains to be made in such kinds of explorations. In the present study, we tried to construct a recombinant vector carrying TK suicide gene and harboring a self-modulating property for gene therapy in an attempt to vanquish HBV infection in a fire-new strategy.

MATERIALS AND METHODS
Materials

Plasmid pcDNA3-TK containing TK gene and pcDNA3-S carrying HBV-S gene were maintained in our laboratory. Eukaryotic expression vector pcDNA3 was from Invitrogen Company, Netherlands. Purification kit for PCR product was obtained from QIAGEN Company (Germany). Reverse transcriptase and PCR amplification system were purchased from Shenzhen Jingmei Company (China) and Expand PCR kit form Stratgene Company (USA). Taq and Pfu enzymes were purchased from Bio-Star Company (Canada). Restriction endonucleases such as EcoR I, BamH I and HinD III, T4 DNA ligase and ELISA kit for detecting HBsAg were from Huamei Bioengineering Company (Luoyang, China). All the PCR primers used in the study were synthesized by Takara Ltd (Dalian, China).

Preparation of gene fragments

The fragments of HCV-IRES element and core gene were obtained by RT-PCR. Total HCV RNA was extracted and purified from 100 μL samples of HCV-positive sera using a guanidium isothiocyanate-acid phenol extraction procedure (Jingmei Company, Shenzhen, China). Precipitated RNA was dissolved in 20 μL of diethyl pyrocarbonate-treated water and quantified by UV spectrum analysis. Specific cDNA for HCV IRES element and core gene were amplified respectively with RT-PCR kit by adding their corresponding primers according to the protocols of Reverse Transcription System (Jingmei Company, Shenzhen, China). The primers for the HCV IRES were sequenced as sense: 5’-GCGCGGATCCGGGCGACACTCCACCATAG-3’ (nucleotides [nt] 17 to 36) and antisense: 5’-GCGAATTCGTTTTTCTTTGAGGTTTAGGATTC-3’ (nt 347 to 371). The primers for the HCV core gene were 5’-TAGGAATCCTGATGAGCACGAATCCTAAACCTC-3’ (sense) and 5’-GCGCGGATCCTTAAGCGGAAGCTGGGATG-3’ (antisense). PCR was performed on the Real-time PCR apparatus (Roche, USA) with a program for 30 cycles at 42 °C for 45 min and at 94 °C for 5 min followed by at 92 °C for 30 s, at 55 °C for 30 s and at 72 °C for 30 s. After prepared by routine procedures, the PCR products were analyzed by agarose gel electrophoresis and stored at -20 °C until use.

The antisense fragment of HBV-S gene lack of initiating codon (ATG) was amplified with the PCR protocol using the oligonucleotide sequence 5’-GCGCGTGCAAGCTTATAAAACGCCGCAGACACATC-3’ (sense) and 5’-ATTCGTGCTCATCAGGATTCCTAGGACCCCTTC-3’ (antisense) as primers, and pcDNA3-S as the template. After an initial denaturation step was performed, PCR was carried out for 45 cycles at 95 °C for 15 s, at 70 °C for 5 s and at 72 °C for 15 s each cycle. The PCR products were identified by electrophoresis on an l% of agarose gel stained with ethidium bromide and stored at -20 °C until use.

TK gene segment was prepared by digestion of plasmid pcDNA3-TK with EcoR I and purified with the routine procedures.

Construction of self-modulated expression vector

The construction scheme for the self-modulated expression vector that can respond to HBV infection and eliminate the infected hepatic cells is shown in Figure 1. Briefly, ligation of antisense fragment of HBV-S gene with HCV-C gene segment was performed by SOEing PCR[26-28], in which the sense sequence of HCV-C gene primer 5’-TAGGAATCCTGATGAGCACGAATCCTAAACCTC-3’ and a truncated antisense sequence of HBV-S gene primer 5’-ATTCGTGCTCATCAGGATTCCTAGGACCCC-3’ were used as primers. The major SOEing PCR round comprised of 30 cycles at 92 °C for 30 s, at 50 °C for 45 s and at 72 °C for 60 s each cycle, and a final extension at 72 °C for 10 min. The ligated PCR products were purified and analyzed by agarose gel electrophoresis and used to link with the HCV-IRES fragment by T4 ligase after both segments were digested by BamH I. The resultant HBV antisense S-HCV C-HCV IRES (SCI) fragment was further amplified by PCR with the major round to be at 92 °C for 30 s, at 53 °C for 45 s and at 72 °C for 60 s for 30 cycles, and the final extension at 72 °C for 10 min, in which HBV-S gene sense primer, 5’-GCGCGTGCAAGCTTATAAAACGCCGCAGACACATC-3, and HCV-IRES antisense primer, 5’-GCGAATTCGTTTTTCTTTGAGGTTTAGGATTC-3’, were employed as primers. After digested by corresponding restriction endonucleases, the amplified HBV antisense S-HCV C-HCV IRES fragment was cloned into Hind III and EcoR I sites of pcDNA3 to generate eukaryotic expression plasmid pcDNA3-SCI (Figure 1). In the same way, the expression plasmid pcDNA3-SCITK was yielded by cloning TK fragment into EcoR I site of pcDNA3-SCI. Both of the newly constructed plasmid were confirmed by restriction endonuclease digestion, PCR with specific primers and finally by DNA sequencing (Baosheng Company, Daliang, China).

Figure 1
Figure 1 Construction scheme of recombinant plasmid pcDNA3-SCITK.
Self-restricted expression of recombinant plasmid

HepG2 and its derived cell line 2.2.15 that carries the full HBV genome and can stably express series of HBV antigen were maintained in our laboratory. They were cultured in a modified Eagal’s essential medium (Sigima) supplemented with 100 U·mL-1 penicillin, 100 U·mL-1 streptomycin, and L-glutamine, nonessential amino acids and sodium bicarbonate in doses recommended by the China Type Culture Collection (Wuhan, China) at 37 °C in a humidified atmosphere containing 5% of CO2. One day prior to transfection, cells were transferred onto an 8-well plate and incubated in complete Dulbecco’s modified Eagle’s medium (DMEM) containing 10% (v/v) fetal calf serum (FCS) and 10 μg/mL of ganciclovir. When the cells grew to 50%-80% confluence, they were transfected with pcDNA3-SCITK or pcDNA3-SCI plasmid in a ratio of per 106 cells to 1 μg of plasmid DNA by LipofectAMINE transfection reagent following the manufacturer’s instructions. (Invitrogen Co. USA). 2.2.15 cells transfected with pcDNA3-SCITK or pcDNA3-SCI plasmids were designated as the experimental group or the mock group. The HepG2 cells transfected with pcDNA3-SCITK plasmids were functioned as the negative control. All of the transfected cells were maintained in DMEM medium with 10% (v/v) fetal calf serum (FCS) and 10 μg/mL of ganciclovir for at least 7 d. The HBsAg levels in the supernatant of cell culture were detected by ELISA on the 1st, 3rd and 6th day after transfection. Meanwhile, the morphology of transfected cells were recorded by the photograph and the survival cell ratio was assessed by the trypan blue exclusion test on the 6th day of posttransfection.

Statistical analysis

Experimental data were processed by analysis of variance and t-test for comparison between groups. Results were expressed as mean ± SE. P < 0.05 was selected as the level of statistical significance.

RESULTS
Structural identification of constructed plasmids

The segment analysis of recombinant plasmid pcDNA3-SCITK by restriction endonuclease digestion and PCR with specific primers demonstrated that the inserted gene sequences in the plasmid were completely consistent with that of the theoretical calculations as shown in Figure 2, which were further confirmed by the DNA sequencing (data not shown).

Figure 2
Figure 2 A: RT-PCR products of HCV IRES element. M: marker (2 kb), Lanes 1-3: HCV IRES element (330 bp). B. Component segment analysis of pcDNA3-SCITK by agarose gel electrophoresis. M: marker (2 kb), Lanes 1-2: SCI-TK fragment demonstrated by PCR with HBV-S gene sense primer and TK antisense primer (5’-ACTTCCGTGGCTTCTTGCTG-3’ (nt 150-170). Lane 3: SCI fragment verified by PCR with HBV-S gene sense primer and HCV IRES antisense primer. Lane 4: SI segment from the ligation of HBV-S and HCV-Core gene by SOEing PCR. Lane 5: RT-PCR product of HCV-Core gene. Lane 6: Partial antisense segment of HBV-S gene.
Effects of pcDNA3-SCITK expression on HBV-infected cells

The expressive efficiency of TK protein by 2.2.15 cells transfected with pcDNA3-SCITK was confirmed in our previous investigations (data to be published). In the present study, the effects of pcDNA3-SCITK transfection on the expression of HBsAg by 2.2.15 cells was observed. The results showed that HBsAg in the supernatant of transfected 2.2.15 cell culture was significantly decreased on the 6th day post-transfection as compared with that of the mock group (P < 0.05, Table 1).

Table 1 HBsAg expression in supernants of cell culture by experimental cells.
GroupsOD Value
1st day3rd day6th day
Mock group0.32 ± 0.130.61 ± 0.230.61 ± 0.25
Experimental group0.31 ± 0.110.51 ± 0.220.41 ± 0.16a

The lethiferous effect of pcDNA3-SCITK expression on 2.2.15 cells was first noted on the 3rd day after transfection and aggravated on the 6th day posttransfection, in which the majority of transfected 2.2.15 cells were observed shrunken, round in shape and even dead (Figure 3). With assessment by the trypan blue exclusion test, the survival cell ratio on the 6th day posttransfection was 95% in the negative control and only 11% in the experimental group.

Figure 3
Figure 3 Effects of pcDNA3-SCITK expression on morphological alterations of 2. 2.15 and HepG2 cells. Photographs a, b and c in each group exhibited respectively the cell changes on the 1st, 3rd and 6th day post transfection. Lethiferous changes of 2.2.15 cells transfected with pcDNA3-SCITK were noted initially on the 3rd day of posttransfection and aggravated on the 6th day after transfection, in which the majority of cells were observed shrunken, rounded in shape and even dead. However, the negative contrl HepG2 cells grew well.
DISCUSSION

Chronic hepatitis B infection remains a major public health problem worldwide. Hepatitis B virus belongs to the family of hepadnaviruses that replicate their DNA genome via a reverse transcription pathway. The chronicity of infection in infected hepatocytes is maintained by the persistence of the viral covalently closed circular DNA. Traditionally, the strategy to combat chronic HBV infection depends mainly on the stimulation of specific antiviral immune response or on the inhibition of viral replication, or on both. However, it has been found that prolonged administration of therapeutic agents is often associated with the production of resistant mutants and serious side effects, as well as a control of viral replication rather than eradication. To further search for effective therapeutic modalities to deal with the chronic infection of HBV is therefore urgently needed to design a brand-new strategy to clear the causative virus.

Hepatitis C virus, a member of the Flaviviridae family and an enveloped virus with a single-stranded 9.6 kb RNA genome of positive polarity[29], utilizes a cap-independent mechanism to initiate translation on its genomic RNAs. This process could involve an internal ribosome entry sites (IRES) located in the 5’ nontranslated RNA (5’-NTR), and both canonical and noncanonical translation initiation factors[30-32]. The former could be constructed in some of the bicistronic systems with a higher efficiency in the initiation of protein translation and has been used to construct recombinant vectors[33-36]. It has been recently found that HCV-C protein, another functional modulator localized both in cytoplasm and in perinuclear regions, could interact with IRES and down-regulate IRES-directed translation[37-42], which has been considered to be involved in the establishment or maintenance of the virus persistence[40-43]. Based on these observations, we hypothesized that a self-modulating mechanism by the interaction of HCV-C protein with IRES element was possible to be employed in gene therapy for the eradication of chronic HBV infection.

In the present study, we constructed a recombinant plasmid pcDNA3-SCITK by cloning HCV-C gene and IRES element, partial antisense sequence of HBV-S gene, and TK suicide gene into the eukaryotic expression vector pcDNA3, in which the expression of TK gene was driven in turn by human cytomegalovirus (CMV) promoter, HBV-anti-S and HCV core-IRES sequences. The prominent feature of this plasmid was the temperate expression of effector gene in transfected cells by a self-modulating mechanism. When HBV in the infected cells began to replicate, the transcribed mRNA of HBV-S gene could be combined with its counterpart produced by HBV-antisense-S gene in the recombinant plasmid to form a mRNA dimmer prior to the initiation codon AUG of HCV-C gene, which brought about a decreased expression of HCV-C protein. The consequently reduced HCV core protein-IRES combination could enhance the IRES element to promote the expression of TK suicide gene and further to cause a lethiferous effect on HBV infected cells. In contrast, the expression of effector gene TK was inhibited in non-infected cells because of the normal level of HCV-C protein expression and its normal combination with HCV-IRES element, which would not cause any damage to the healthy cells.

In order to identify the anti-HBV efficiency of pcDNA3-SCITK, 2.2.15 cells that carry the full HBV genome and can stably express series of HBV antigen were transfected with the plasmid. The results showed that HBsAg level in the supernatant of transfected 2.2.15 cell culture was significantly decreased on the 6th day post transfection as compared with that of the mock cells (Table 1). The lethiferous effect of pcDNA3-SCITK expression on 2.2.15 cells was noted initially on the 3rd day after transfection and aggravated on the 6th day posttransfection, in which the majority of transfected 2.2.15 cells were observed shrunken, round in shape and even dead. However, the negative control HepG2 cells grew well (Figure 3). With assessment by the trypan blue exclusion test, the survival cell ratio on the 6th day post transfection was 95% in the negative control and only 11% in the experimental group. All these observations confirmed that plasmid pcDNA3-SCITK could exert a lethiferous effect on HBV infected cells via a self-modulating mechanism, which might also be served as a potential therapeutic strategy for the liver cancers derived from chronic HBV infection.

The limitation of the present study is the neglect of anti-HBV infection by preventing the pathogen from invading target cells or by interrupting the virus replication at the beginning of the disease. How to apply our present therapeutic strategy in combination with other treatment protocols to the eradication of chronic HBV infection is to be further investigated.

Footnotes

Edited by Wang XL

References
1.  Xu R, Cai K, Zheng D, Ma H, Xu S, Fan ST. Molecular therapeutics of HBV. Curr Gene Ther. 2003;3:341-355.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 14]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
2.  Morrissey DV, Lee PA, Johnson DA, Overly SL, McSwiggen JA, Beigelman L, Mokler VR, Maloney L, Vargeese C, Bowman K. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. J Viral Hepat. 2002;9:411-418.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 18]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
3.  Gumina G, Song GY, Chu CK. Advances in antiviral agents for hepatitis B virus. Antivir Chem Chemother. 2001;12 Suppl 1:93-117.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Feng Y, Kong YY, Wang Y, Qi GR. Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes. J Gastroenterol Hepatol. 2001;16:1125-1130.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 18]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
5.  Staschke KA, Colacino JM. Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res. 2001;Spec No:111-183.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Harrison GL, Murray-McIntosh R, Penny D. Hepatitis B virus genotypes: a South Pacific perspective. Pac Health Dialog. 2001;8:188-192.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Zoulim F. Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Res. 1999;44:1-30.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 35]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
8.  Merle P, Trépo C, Zoulim F. Current management strategies for hepatitis B in the elderly. Drugs Aging. 2001;18:725-735.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 22]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
9.  Bernardi M, Biselli M, Gramenzi A. [Chronic hepatitis B. Recent advances in diagnosis and treatment]. Recenti Prog Med. 2002;93:397-402.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Fang JN, Jin CJ, Cui LH, Quan ZY, Choi BY, Ki M, Park HB. A comparative study on serologic profiles of virus hepatitis B. World J Gastroenterol. 2001;7:107-110.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol. 2001;7:208-215.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Roussos A, Goritsas C, Pappas T, Spanaki M, Papadaki P, Ferti A. Prevalence of hepatitis B and C markers among refugees in Athens. World J Gastroenterol. 2003;9:993-995.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002;9:393-399.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 55]  [Cited by in F6Publishing: 62]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
14.  Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol. 2003;13:255-272.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 35]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
15.  Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother. 2003;51:761-785.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 75]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
16.  Raj V. Treatment of hepatitis B. Clin Cornerstone. 2001;3:24-36.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 10]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
17.  Zoulim F, Trepo C. New antiviral agents for the therapy of chronic hepatitis B virus infection. Intervirology. 1999;42:125-144.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 23]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
18.  Klein C, Bock CT, Wedemeyer H, Wüstefeld T, Locarnini S, Dienes HP, Kubicka S, Manns MP, Trautwein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology. 2003;125:9-18.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 140]  [Cited by in F6Publishing: 152]  [Article Influence: 7.2]  [Reference Citation Analysis (0)]
19.  Wo JE, Wu XL, Zhu HH, Zhou LF, Yao HP, Chen LW. [DNAzymes in vitro inhibit the expression of hepatitis B virus genes]. Zhejiang Daxue Xuebao Yixueban. 2003;32:112-115.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Tung FY, Bowen SW. Targeted inhibition of hepatitis B virus gene expression: a gene therapy approach. Front Biosci. 1998;3:a11-a15.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Guha C, Shah SJ, Ghosh SS, Lee SW, Roy-Chowdhury N, Roy-Chowdhury J. Molecular therapies for viral hepatitis. BioDrugs. 2003;17:81-91.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Wu C, Zeng Z, Wang Q. [Experimental study of inhibition of hepatitis B by dual-target antisense RNA]. Zhonghua Yixue Zazhi. 2001;81:605-608.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Robaczewska M, Guerret S, Remy JS, Chemin I, Offensperger WB, Chevallier M, Behr JP, Podhajska AJ, Blum HE, Trepo C. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Ther. 2001;8:874-881.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 38]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
24.  Feng Y, Kong YY, Wang Y, Qi GR. Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells. Biol Chem. 2001;382:655-660.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Zu Putlitz J, Wieland S, Blum HE, Wands JR. Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology. 1998;115:702-713.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 25]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
26.  Yang YS, Watson WJ, Tucker PW, Capra JD. Construction of recombinant DNA by exonuclease recession. Nucleic Acids Res. 1993;21:1889-1893.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 38]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
27.  Horton RM. In vitro recombination and mutagenesis of DNA. SOEing together tailor-made genes. Methods Mol Biol. 1997;67:141-149.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Horton RM. PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes. Mol Biotechnol. 1995;3:93-99.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol. 2000;81:1631-1648.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 356]  [Cited by in F6Publishing: 481]  [Article Influence: 20.0]  [Reference Citation Analysis (0)]
30.  Reynolds JE, Kaminski A, Kettinen HJ, Grace K, Clarke BE, Carroll AR, Rowlands DJ, Jackson RJ. Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J. 1995;14:6010-6020.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Ander-son WF. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 1992;25:1293-1299.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 161]  [Cited by in F6Publishing: 175]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
32.  Lu HH, Wimmer E. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. Proc Natl Acad Sci USA. 1996;93:1412-1417.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 125]  [Cited by in F6Publishing: 137]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
33.  Urabe M, Hasumi Y, Ogasawara Y, Matsushita T, Kamoshita N, Nomoto A, Colosi P, Kurtzman GJ, Tobita K, Ozawa K. A novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome. Gene. 1997;200:157-162.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 28]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
34.  Kruger M, Beger C, Li QX, Welch PJ, Tritz R, Leavitt M, Barber JR, Wong-Staal F. Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach. Proc Natl Acad Sci USA. 2000;97:8566-8571.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 74]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
35.  Zhang H, Hanecak R, Brown-Driver V, Azad R, Conklin B, Fox MC, Anderson KP. Antisense oligonucleotide inhibition of hepa-titis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother. 1999;43:347-353.  [PubMed]  [DOI]  [Cited in This Article: ]
36.  Liang XS, Lian JQ, Zhou YX, Nie QH, Hao CQ. A small yeast RNA inhibits HCV IRES mediated translation and inhibits replication of poliovirus in vivo. World J Gastroenterol. 2003;9:1008-1013.  [PubMed]  [DOI]  [Cited in This Article: ]
37.  Santolini E, Migliaccio G, La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol. 1994;68:3631-3641.  [PubMed]  [DOI]  [Cited in This Article: ]
38.  Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi SI, Ichikawa M, Kajita T, Moradpour D, Wands JR, Kohara M. The native form and maturation process of hepatitis C virus core protein. J Virol. 1998;72:6048-6055.  [PubMed]  [DOI]  [Cited in This Article: ]
39.  Urabe M, Hasumi Y, Ogasawara Y, Matsushita T, Kamoshita N, Nomoto A, Colosi P, Kurtzman GJ, Tobita K, Ozawa K. A novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome. Gene. 1997;200:157-162.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 28]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
40.  Shimoike T, Mimori S, Tani H, Matsuura Y, Miyamura T. Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. J Virol. 1999;73:9718-9725.  [PubMed]  [DOI]  [Cited in This Article: ]
41.  Zhang J, Yamada O, Yoshida H, Iwai T, Araki H. Autogenous translational inhibition of core protein: implication for switch from translation to RNA replication in hepatitis C virus. Virology. 2002;293:141-150.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 45]  [Cited by in F6Publishing: 50]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
42.  Li D, Takyar ST, Lott WB, Gowans EJ. Amino acids 1-20 of the hepatitis C virus (HCV) core protein specifically inhibit HCV IRES-dependent translation in HepG2 cells, and inhibit both HCV IRES- and cap-dependent translation in HuH7 and CV-1 cells. J Gen Virol. 2003;84:815-825.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 35]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
43.  Yao ZQ, Ray S, Eisen-Vandervelde A, Waggoner S, Hahn YS. Hepatitis C virus: immunosuppression by complement regulatory pathway. Viral Immunol. 2001;14:277-295.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 48]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]